Core Viewpoint - Optima Health's partnership with Perkbox is strategically significant, enhancing distribution capabilities more than contributing directly to revenue growth [2][3]. Group 1: Contract Details - The annual contract with Perkbox is valued at £6.5 million and is part of an £8.3 million new business pipeline disclosed in Optima's December half-year results [3]. - This partnership provides Optima with direct access to Perkbox's corporate client base, which would have otherwise required extensive sales efforts to reach [3]. Group 2: Growth Strategy - Optima's growth strategy increasingly relies on securing large-scale contracts in both public and private sectors, as evidenced by the £290 million Armed Forces deal and the upcoming acquisition of People Asset Management (PAM) [4]. - The addition of an established employee benefits platform like Perkbox as a distribution partner enhances Optima's market reach without incurring significant costs [5]. Group 3: Valuation Context - Optima is currently trading at approximately 185p, which equates to about 6.8 times the forecast FY27 EV/EBITDA, compared to acquisition multiples in the sector ranging from 12 to 15 times [5]. - Despite a series of contract wins and being described as a profitable, cash-generative business with substantial acquisition capacity, the valuation discount has persisted [5]. Group 4: Future Outlook - While the recent deal may not immediately alter the valuation discount, it reinforces Optima's methodical approach to building scale in the market [6].

Core Viewpoint - RBC Capital Markets maintains an 'outperform' rating on Optima Health PLC and a price target of 240p following the £100m acquisition of People Asset Management Healthcare, which solidifies Optima's leading position in the UK occupational health market with a 15% market share in a £1.6bn industry [1][2]. Group 1: Acquisition Details - The acquisition of People Asset Management Healthcare, one of the top four outsourced providers, removes a key competitor and accelerates Optima's medium-term revenue target of £200m and adjusted EBITDA target of £40m, aiming for a 25% market share [2]. - The £100m acquisition consideration is approximately 12.2 times the 2025 adjusted EBITDA and will be financed through £70m of existing bank facilities and a £30m interest-free bridge loan from Optima's largest shareholder [3]. Group 2: Financial Projections - RBC forecasts combined revenue of £205m and adjusted EBITDA of £28.5m for 2027, indicating a 13.9% margin, including £1m in cost synergies, with estimated earnings per share of around 14.1p, reflecting a 2.5% accretion in the first year [5]. - Cost synergies are expected to increase to £4.5m by year three, with earnings accretion projected to exceed 20% by 2029 [5]. Group 3: Valuation and Market Position - RBC anticipates leverage to rise to approximately 2.7 times net debt to EBITDA at completion, with a reduction to about one times within three years due to PAM's cash conversion rate exceeding 60% [4]. - A pro forma equity value of 255p per share is calculated based on a 10.5 times multiple of 2027 enterprise value to adjusted EBITDA, aligning with discounted cash flow valuation methods [6]. - The acquisition is seen as a strategic enhancement to Optima's scale and market position, with execution and regulatory timing being critical near-term factors [7].

Core Viewpoint - Optima Health's acquisition of PAM Healthcare for approximately £100 million is seen as a strategic move to enhance its market position in the UK outsourced occupational health sector, aiming for a dominant market share and improved financial performance [1][2][3]. Market Position and Growth - The acquisition will increase Optima's pro forma market share to about 15% in the £1.6 billion UK and Republic of Ireland occupational health market, positioning it as a clear market leader [2][3]. - This deal is expected to significantly accelerate Optima's revenue target of £200 million and adjusted EBITDA target of £40 million in the medium term [2]. Valuation and Financial Impact - The acquisition is valued at approximately 12.2 times historic adjusted EBITDA, with a forward multiple of about 9.6 times, which is slightly below Optima's own trading multiple [4]. - Following the acquisition, Cavendish has revised its adjusted EBITDA forecasts for the years ending March 2027 and March 2028, increasing expectations to £28.2 million from £19.6 million and £34.4 million from £22.4 million, respectively [6]. Financing Structure - Optima plans to finance the acquisition through £70 million in new bank facilities and a £30 million bridge loan from Deacon Street Partners, its largest shareholder [5]. - An open offer of £35 million will be launched at a price of 175p to repay the bridge loan and cover associated costs, allowing for quick cash payment without the risk of a placing [6]. Future Projections - The combination of Optima and PAM Healthcare is expected to generate significant economies of scale, supporting margin improvement over time [7]. - Target prices have been set at 271p by Cavendish and 225p by Panmure, with a pro forma value of 250p anticipated once the deal and open offer are finalized [7]. Current Stock Performance - As of early afternoon trading, Optima's stock was priced at 209.9p [8].